Cancer diagnostics

GLYVAR™ Ovarian Assay – an advanced solution for early-stage ovarian cancer detection

Currently available as Research Use Only (RUO), the GLYVAR™ Ovarian assay is a quantitative, non-competitive immunoassay measuring cancer-specific glycan structures on the CA-125 protein marker.

Key Benefits*:

• Outperforms conventional CA-125 assays: Increased detection from 33% to 83% in women with marginally elevated CA-125 levels. 66% higher detection rate for early-stage high grade serous carcinomas.
• Better differentiation: Distinguishes cancer cases from benign tumours and conditions like endometriosis. GLYVAR™ Ovarian removed 82% of the false positives generated when using CA-125 protein test.
• Accessible technology: Compatible with standard laboratory equipment making it suitable for a wide range of settings.

*The data is from a recent publication in Clinical Chemistry and Laboratory Medicine, which highlights the advantages of our GLYVAR™ Ovarian test and underscores the potential of glycovariant diagnostics to transform ovarian cancer detection.

“There is an unmet need for creation of diagnostic tools, which can identify ovarian cancer at its earliest and most treatable stages. Ovarian cancer is often diagnosed at an advanced stage due to the lack of effective early detection methods, significantly reducing the chances of successful treatment. We have seen firsthand the impact that the late-stage diagnosis can have on patients and their families. We are hopeful that Uniogen’s innovative approach will help change this narrative for the better.“

---

Future directions in cancer diagnostics

The GLYVAR™ Ovarian Assay is an important first step in our broader vision. Uniogen is committed to advancing cancer diagnostics with a focus on women’s health and beyond. Our roadmap includes developing additional glycovariant-based tests and leveraging our expertise to address unmet clinical needs globally.

Patented Innovations:
Uniogen holds patents for glycovariant-based testing of other cancer types, including e.g., pancreatic, breast, and intestinal cancers, reinforcing our long-term vision to deliver accurate and accessible diagnostics across multiple indications